Latest News and Press Releases

VY-AADC01 interim Phase 1b data recently presented at American Academy of Neurology and American Association of Neurological Surgeons meetings; program on track to report 6-month data from Cohort 3...

CAMBRIDGE, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the...

Improved Functional and Quality of Life Data Presented at the American Academy of Neurology (AAN) Meeting in Boston, MA Surgical Delivery Data Presented at the American Association of Neurological...

Lead program VY-AADC01 for advanced Parkinson’s disease on track to report 6-month data from Cohort 3 and longer-term data from Cohorts 1 and 2 in mid-year 2017 VY-AADC01 Phase 1b data accepted as...

CAMBRIDGE, Mass., March 08, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the...

CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the...

VY-SOD101 Selected Based on Robust Delivery and Knock-Down of Toxic SOD1 in Preclinical Models Program On Track for IND filing during 4Q:17 CAMBRIDGE, Mass., Feb. 13, 2017 (GLOBE NEWSWIRE) --...

CAMBRIDGE, Mass., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the...

Single Administration of AAV-Vectored Anti-Tau Monoclonal Antibody Markedly Reduced Tau Pathology in Preclinical Model Voyager Optimizing the Delivery of Anti-Tau Monoclonal Antibodies with its...

Cohort 3 Enrollment Complete with Increased Coverage of the Putamen Observed Cohort 3 On Track for Six-Month Data Update Mid-2017 CAMBRIDGE, Mass., Jan. 20, 2017 (GLOBE NEWSWIRE) -- Voyager...